What changed
$BMY — Pharmaceutical company developing prescription medicines and therapies.
🎯 Q1 FY26 | Rev $11B | EPS $1.58 vs $1.42 🟢
💡 Consensus expects BMY's beat to be a one-off driven by cost cuts, but the 11% EPS beat came on only 3% revenue growth and a 23% net margin that may not be sustainable given rising R&D spend (23% of revenue) and weak operating cash flow ($1.1B vs $1.95B a year ago).
🏢 Business Quality: 6/10 | Valuation: fair
📉 Reward/Risk: Upside 10% to $61 (if cash flow recovers and pipeline de-risks) vs downside 15% to $47 (if revenue stalls or debt concerns rise). Ratio ~0.7:1, unfavorable.
🔮 Catalyst: Next earnings (late July 2026) must show revenue acceleration and cash flow recovery. Key metric: operating cash flow >$2B. Failure signal: revenue growth <2% or cash flow decline.
Also in play: $PFE $MRK $JNJ $ABBV $LLY $CNC